繁體版 / 簡體版
 
R&D PORTFOLIO
/ OB-318

OB-318

Indication
New Anti-cancer Drug
Mechanism
Mechanism of Action: Composite mechanism of action effectively inhibit the growth, metastasis, and angiogenesis of tumor.
Status
USFDA and TFDA approved phase I clinical trials.
Product Advantages
1.Efficacy: significantly inhibit the growth of tumor in allogenic subcutaneous xenograft model or refractory orthotopic xenograft model of maliligant cancers.
2.Safety: The concentration ratio that inhibit cancer cells and normal cells reaches 100 times, with optimal selectively.
3.Quality: standard quality control procedures to effectively control active ingredients from the fermentation of raw materials to final products.
4.Exclusiveness: Antrodia cinnamomea is an endemic species of Taiwan, with related research and development leading the world. Foreign competitors can hardly have access to the raw materials.
Potential Market
The market for anti-liver cancer drugs was about 24.5 billion US dollars in 2014. It is expected to grow to 33.8 billion US dollars in 2019.
  • The OB318 is according the ICH guideline and USFDA published standards to execut the pre-clinical research. All the technologies and quality are followed the international standards. Multiple cancer cell lines and normal cell line were used to evaluate the anticancer activity and safety range. The anticancer activity of OB318 was also verified by different animal models of diseases.


陕西快乐十分中奖技巧 mg电子游戏娱乐成网站 (*^▽^*)MG百搭圣甲虫首页 (-^O^-)MG搞笑斑马游戏规则 1-9幸运数字含义 赛马会赛马会论坛 (^ω^)MG泰国天堂爆分技巧 广东26选5尾数走势图 青海快3开奖号码 九天国际彩票平台 (^ω^)MG奇妙马戏团怎么玩容易爆分 今天内蒙古快3专家预测 (^ω^)MG快乐假日_豪华版 (*^▽^*)MG亚特兰蒂斯女王免费试玩 (★^O^★)MG捷豹的传说_最新版 广西快3开结果 互联网彩票政策最新消息